ADMA BIOLOGICS, INC. Business Acquisition, Pro Forma Net Income (Loss)
ADMA BIOLOGICS, INC. (ADMA) reported Business Acquisition, Pro Forma Net Income (Loss) of -$52.93 million for the 12-month period ending 2017-12-31, per its 10-K filed 2019-03-13.
Discontinued › Expense Statement › Operating Expenses
us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss · last filed 2019-03-13
- ADMA BIOLOGICS, INC. business acquisition, pro forma net income (loss) for the quarter ending 2017-12-31 was -$12.90M.
- ADMA BIOLOGICS, INC. business acquisition, pro forma net income (loss) for the quarter ending 2017-09-30 was -$15.20M.
- ADMA BIOLOGICS, INC. business acquisition, pro forma net income (loss) for the quarter ending 2017-06-30 was -$12.75M.
- ADMA BIOLOGICS, INC. business acquisition, pro forma net income (loss) for the quarter ending 2017-03-31 was -$12.77M.
- ADMA BIOLOGICS, INC. business acquisition, pro forma net income (loss) for fiscal 2017 was -$52.93M.
- ADMA BIOLOGICS, INC. business acquisition, pro forma net income (loss) for fiscal 2016 was -$82.98M.
| Period end | Business Acquisition, Pro Forma Net Income (Loss) 3 month | Business Acquisition, Pro Forma Net Income (Loss) 6 month | Business Acquisition, Pro Forma Net Income (Loss) 9 month | Business Acquisition, Pro Forma Net Income (Loss) 12 month |
|---|---|---|---|---|
| 2017-12-31 | -$12.90M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-13 | -$28.10M derived: sum of 2 quarters · filed 2019-03-13 | -$40.85M derived: sum of 3 quarters · filed 2019-03-13 | -$52.93M 10-K · filed 2019-03-13 |
| 2017-09-30 | -$15.20M 10-Q · filed 2018-11-09 | -$27.95M derived: sum of 2 quarters · filed 2018-11-09 | -$40.03M 10-Q · filed 2018-11-09 | -$71.74M derived: sum of 4 quarters · filed 2018-11-09 |
| 2017-06-30 | -$12.75M 10-Q · filed 2018-08-10 | -$24.83M 10-Q · filed 2018-08-10 | -$56.54M derived: sum of 3 quarters · filed 2018-08-10 | -$78.02M derived: sum of 4 quarters · filed 2018-08-10 |
| 2017-03-31 | -$12.77M 10-Q · filed 2018-05-14 | -$43.79M derived: sum of 2 quarters · filed 2018-05-14 | -$65.27M derived: sum of 3 quarters · filed 2018-05-14 | -$79.75M derived: sum of 4 quarters · filed 2018-05-14 |
| 2016-12-31 | -$31.01M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-29 | -$52.50M derived: sum of 2 quarters · filed 2018-03-29 | -$66.97M derived: sum of 3 quarters · filed 2018-03-29 | -$82.98M 10-K · filed 2018-03-29 |
| 2016-09-30 | -$21.48M 10-Q · filed 2017-11-03 | -$35.96M derived: sum of 2 quarters · filed 2017-11-03 | -$51.97M 10-Q · filed 2017-11-03 | |
| 2016-06-30 | -$14.47M 10-Q · filed 2017-08-11 | -$29.07M 10-Q · filed 2017-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |